Residual disease-guided strategy combining ibrutinib and venetoclax for the treatment of relapsed or refractory chronic lymphocytic leukemia

被引：0
|
作者：
Stocker, Nicolas
机构：
来源：
HEMATOLOGIE | 2022年 / 28卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：174 / 175
页数：2
相关论文
共 50 条
  • [1] Venetoclax Combined With Ibrutinib Based on a Minimal Residual Disease-Guided Approach in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the IMPROVE Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 19 - 20
  • [2] Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
    Niemann, Carsten U.
    Levin, Mark-David
    Dubois, Julie
    Kersting, Sabina
    Enggaard, Lisbeth
    Veldhuis, Gerrit J.
    Mous, Rogier
    Mellink, Clemens H. M.
    Dobber, Johan A.
    Poulsen, Christian B.
    Frederiksen, Henrik
    Janssens, Ann
    Schjodt, Ida
    Dompeling, Ellen C.
    Ranti, Juha
    Mattsson, Mattias
    Bellido, Mar
    Tran, Hoa T. T.
    Nasserinejad, Kazem
    Kater, Arnon P.
    BLOOD, 2021, 137 (08) : 1117 - 1120
  • [3] Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
    Hillmen, Peter
    Rawstron, Andy C.
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca J.
    Bishop, Rebecca
    Boucher, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers E. M.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Munir, Talha
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2722 - +
  • [4] Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
    Izutsu, Koji
    Yamamoto, Kazuhito
    Kato, Koji
    Ishikawa, Takayuki
    Fukuhara, Noriko
    Terui, Yasuhito
    Choi, Ilseung
    Okubo, Sumiko
    Ogawa, Natsumi
    Sakai, Mizu
    Nishimura, Yasuko
    Chyla, Brenda
    Sun, Yan
    Maruyama, Dai
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (04) : 526 - 528
  • [5] Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
    Koji Izutsu
    Kazuhito Yamamoto
    Koji Kato
    Takayuki Ishikawa
    Noriko Fukuhara
    Yasuhito Terui
    Ilseung Choi
    Sumiko Okubo
    Natsumi Ogawa
    Mizu Sakai
    Yasuko Nishimura
    Brenda Chyla
    Yan Sun
    Dai Maruyama
    International Journal of Hematology, 2023, 118 : 526 - 528
  • [6] Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Burger, Jan A.
    Ferrajoli, Alessandra
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Bose, Prithviraj
    Fowler, Nathan H.
    Kadia, Tapan M.
    Daver, Naval G.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
  • [7] Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Brown, J. R.
    Eichhorst, B.
    Hillmen, P.
    Jurczak, W.
    Kazmierczak, M.
    Lamanna, N.
    O'Brien, S. M.
    Tam, C. S.
    Qiu, L.
    Zhou, K.
    Simkovic, M.
    Mayer, J.
    Gillespie-Twardy, A.
    Ferrajoli, A.
    Ganly, P. S.
    Weinkove, R.
    Grosicki, S.
    Mital, A.
    Robak, T.
    Osterborg, A.
    Yimer, H. A.
    Salmi, T.
    Wang, M. -D. -Y.
    Fu, L.
    Li, J.
    Wu, K.
    Cohen, A.
    Shadman, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (04): : 319 - 332
  • [8] Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Lesley J. Scott
    Targeted Oncology, 2019, 14 : 493 - 504
  • [9] Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2019, 14 (05) : 493 - 504
  • [10] Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia
    Rogers, Kerry A.
    Huang, Ying
    Ruppert, Amy S.
    Abruzzo, Lynne V.
    Andersen, Barbara L.
    Awan, Farrukh T.
    Bhat, Seema A.
    Dean, Allison
    Lucas, Margaret
    Banks, Christin
    Grantier, Cara
    Heerema, Nyla A.
    Lozanski, Gerard
    Maddocks, Kami J.
    Valentine, Thomas R.
    Weiss, David M.
    Jones, Jeffrey A.
    Woyach, Jennifer A.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3626 - +
12345